Congo Deploys Ebola Vaccine Against History's Fastest-Growing Outbreak

A Race Against the Deadliest Ebola Surge Ever Recorded

Ituri province in northeastern Democratic Republic of the Congo is the epicenter of the fastest-growing Ebola outbreak in history. And the numbers make that label viscerally real. The virus has killed at least 3,639 people and infected some 7,541 since May. Only 1,823 have recovered, according to the latest figures from local authorities. With the crisis deepening by the week, health officials have now taken a significant — if uncertain — step to protect those fighting on the front lines.

The vaccine rollout began on Saturday, September 19, in Bunia, the capital of Ituri province. Some 50,000 health and other frontline workers will be injected with the Ervebo vaccine, which was developed for use against the more common Zaire strain. The operation, backed by the World Health Organization and Doctors Without Borders (MSF), will also target North Kivu, where cases have been rising sharply. The scale of the response reflects just how dire the situation has become.

A Vaccine Built for a Different Enemy

Here lies the central challenge — and the central gamble. Clinical trials are ongoing to find a licensed vaccine for the latest outbreak, which has no licensed vaccine or proven treatment. The current outbreak is caused by the Bundibugyo strain of Ebola, not the Zaire strain that Ervebo was specifically designed to fight. As Steve Ahuka, a Congolese official on the health task force, plainly put it: "We don't know to what degree it might be effective against the Bundibugyo strain."

WHO experts have said that early data on the Ervebo vaccine, notably from animal trials, suggested it could offer some protection in the current outbreak. That is a thin thread of hope, but in the absence of any approved alternative, it is the thread officials are pulling. Its effectiveness against the Bundibugyo virus will be monitored in 20,000 recipients for up to one year — turning a portion of the rollout into a real-world clinical trial conducted in the middle of an active catastrophe.

Frontline Workers With No Real Choice

For the healthcare workers actually receiving the jab, the uncertainty is something they are simply learning to live with. Dr. Jeannot Elua, speaking at a health facility in Bunia, said the vaccine was "beneficial" — but added bluntly, "We healthcare workers don't really have a choice. We are going to receive it." It is a sobering statement that captures the impossible position of medical staff in the region. They are being asked to treat a deadly disease with tools that were not made for it, in a place where the alternative is nothing at all.

Adding to the strain, aid workers note that many health workers have gone on strike to protest a lack of payment for their work since the outbreak was declared. Compounding the medical emergency is the security landscape in eastern and northeastern regions, which are heavily impacted by armed groups — forcing public health responders to repeatedly play catch-up as they scramble to halt the spread. The Ituri provincial governor, Major-General Gaby Kasongo Mulumba, acknowledged that health workers "are particularly exposed and deeply involved in the response."

What Comes Next

The Africa Centres for Disease Control and Prevention has confirmed that the current outbreak is the fastest-growing Ebola outbreak ever recorded — not only among previous Bundibugyo outbreaks, but across all known Ebola virus strains. That distinction carries enormous weight for global health officials watching this crisis unfold. As of early September, cases had already spread beyond the DRC, with 20 confirmed in Uganda and one in France.

Trials for three potential vaccines specifically targeting the Bundibugyo strain are expected to begin by October or November, according to the WHO. Until then, Ervebo remains the only tool available — imperfect, untested against this particular virus in humans, but deployed anyway because waiting is no longer an option. The coming months will reveal whether this calculated risk pays off, and whether the world's health institutions can move fast enough to match an outbreak that has already rewritten the record books.